bacterial metabolite

ChEBI CHEBI:76969
Associated conditions

Datasets

Papers Phenotype Conditions Collection Tested mutants Data Details
Chan TF~Zheng XF, 2000 growth (streaks on agar) rapamycin [25 nM] hap a ~2,216 Discrete
Alamgir M~Golshani A, 2010 growth (colony size) streptomycin [40 mg/ml] hap a 4,669 Quantitative
Alamgir M~Golshani A, 2010 growth (colony size) cycloheximide [45 ng/ml] hap a 4,669 Quantitative
Xie MW~Huang J, 2005 growth (colony size) rapamycin [10 nM] hap a/het 5,784 Quantitative
Xie MW~Huang J, 2005 growth (colony size) rapamycin [30 nM] hap a/het 5,784 Quantitative
Kwak YS~Weller DM, 2011 growth (spot assay) 2,4-diacetylphloroglucinol [200 ug/ml] hap a 4,945 Discrete
Blackburn AS~Avery SV, 2003 growth (MIC) oxytetracyclin [256 ug/ml] hap a ~4,800 Discrete
Blackburn AS~Avery SV, 2003 growth (MIC) vancomycin [256 ug/ml] hap a ~4,800 Discrete
Parsons AB~Boone C, 2004 growth (colony size) rapamycin [0.015 ug/ml] hap a ~4,700 Discrete
Parsons AB~Boone C, 2004 growth (colony size) cycloheximide [0.1 ug/ml] hap a ~4,700 Discrete
Kwak YS~Weller DM, 2011 growth (culture turbidity) 2,4-diacetylphloroglucinol [40 ug/ml] hap a 4,945 Quantitative
Neklesa TK~Davis RW, 2008 growth (relative abundance in pooled culture) rapamycin [7.5 ng/ml] hom ~4,757 Discrete
Parsons AB~Boone C, 2006 growth (relative abundance in pooled culture) amphotericin B [0.76 uM] hap a 4,111 Quantitative
Parsons AB~Boone C, 2006 growth (relative abundance in pooled culture) nigericin [69 uM] hap a 4,111 Quantitative
Parsons AB~Boone C, 2006 growth (relative abundance in pooled culture) oligomycin [127 uM] hap a 4,111 Quantitative
Parsons AB~Boone C, 2006 growth (relative abundance in pooled culture) rapamycin [5.5 pM] hap a 4,111 Quantitative
Parsons AB~Boone C, 2006 growth (relative abundance in pooled culture) trichostatin A [99.2 uM] hap a 4,111 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) time [overnight + 20 generations], aclarubicin [32.25 uM] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [0.31 uM], time [overnight + 20 generations] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) time [overnight + 20 generations], cycloheximide [32.3 uM] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) rapamycin [4.88 nM], time [overnight + 20 generations] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) time [overnight + 20 generations], rapamycin [5 nM] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) rapamycin [6 nM], time [overnight + 20 generations] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) rapamycin [9 nM], time [5 generations] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) time [overnight + 10 generations], rapamycin [9 nM] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) time [overnight + 5 generations], rapamycin [9 nM] hom 4,742 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) Bafilomycin A1 [43.69 uM] hom 4,511 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) trichostatin A [200 uM] hom 4,501 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) ascomycin [100 uM] hom 4,518 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) ravidomycin [12.745 uM] hom 4,516 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) boromycin [4 uM] hom 4,508 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) rapamycin [1 nM] hom 4,516 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) aclarubicin [4.857 uM] hom 4,511 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) nigericin [12 uM] hom 4,489 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) cycloheximide [0.03 uM] hom 4,544 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) soraphen A [0.5 uM] hom 4,489 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) chondramide [90 uM] hom 4,507 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) hygrolidin [7.5 uM] hom 4,496 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) borrelidin [45 uM] hom 4,543 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) nigericin [8 uM] hom 4,511 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) Azalomycin B [30 uM] hom 4,520 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) zeocin [0.01 uM] hom 4,539 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) ravidomycin [10 uM] hom 4,506 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) rapamycin [0.2 nM] hom 4,516 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) rapamycin [0.5 nM] hom 4,516 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) rapamycin [0.8 nM] hom 4,516 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) cycloheximide [0.05 uM] hom 4,544 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) chondramide [110 uM] hom 4,525 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) nigericin [15 uM] hom 4,503 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) zeocin [0.012 uM] hom 4,514 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) zeocin [0.05 uM] hom 4,542 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) zeocin [0.1 uM] hom 4,539 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) zeocin [0.3 uM] hom 4,539 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) tacrolimus [29.80 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) rapamycin [4.00 nM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) amphotericin B [148.00 nM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) rapamycin [2.00 nM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) rapamycin [362.00 pM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) cycloheximide [667.00 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) beta-caryophyllene alcohol [24.72 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) daunomycin [18.50 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) daunomycin [22.37 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) amphotericin B [100.00 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) rapamycin [1.00 nM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) tacrolimus [100.00 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) aclarubicin [5.55 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) daunomycin [9.88 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) nigericin [15.30 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) ikarugamyin [104.00 uM] hom 4,810 Quantitative
Lum PY~Shoemaker DD, 2004 growth (relative abundance in pooled culture) minimal complete [standard], amphotericin B [600 ng/ml] het 3,503 Quantitative only for hits
Lum PY~Shoemaker DD, 2004 growth (relative abundance in pooled culture) minimal complete [standard], cycloheximide [10 ng/ml] het 3,503 Quantitative only for hits
Lum PY~Shoemaker DD, 2004 growth (relative abundance in pooled culture) minimal complete [standard], daunomycin [40 ng/ml] het 3,503 Quantitative only for hits
Dudley AM~Church GM, 2005 growth (spot assay) cycloheximide [0.18 ug/ml] hom 4,621 Discrete
Dudley AM~Church GM, 2005 growth (spot assay) rapamycin [0.1 ug/ml] hom 4,621 Discrete
Neklesa TK~Davis RW, 2009 protein activity rapamycin [20ng/ml] hom/het? ~5,100 Discrete
Jakubkova M~Tomaska L, 2016 growth (spot assay) nigericin [0.15-0.5 mg/l] hap a 4,993 Discrete
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) Bafilomycin A1 [43.69 uM] het 5,801 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) ascomycin [100 uM] het 5,801 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) ravidomycin [12.745 uM] het 5,782 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) boromycin [4 uM] het 5,770 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) aclarubicin [4.857 uM] het 5,801 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) nigericin [12 uM] het 5,790 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) cycloheximide [0.03 uM] het 5,810 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) soraphen A [0.5 uM] het 5,790 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) chondramide [90 uM] het 5,768 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) hygrolidin [7.5 uM] het 5,770 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) borrelidin [45 uM] het 5,780 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) nigericin [8 uM] het 5,794 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) Azalomycin B [30 uM] het 5,801 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) zeocin [0.01 uM] het 5,786 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) ravidomycin [10 uM] het 5,786 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) rapamycin [0.2 nM] het 5,782 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) rapamycin [0.5 nM] het 5,782 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) rapamycin [0.8 nM] het 5,782 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) cycloheximide [0.05 uM] het 5,810 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) nigericin [15 uM] het 5,779 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) zeocin [0.012 uM] het 5,802 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) zeocin [0.05 uM] het 5,804 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) zeocin [0.1 uM] het 5,786 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [0.31 uM], time [overnight + 20 generations] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) rapamycin [4.88 nM], time [overnight + 20 generations] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) time [overnight + 20 generations], rapamycin [5 nM] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) rapamycin [6 nM], time [overnight + 20 generations] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) 5-fluoro-cytosine [15.6 uM], amphotericin B [40 uM], time [overnight + 20 generations] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [20 uM], time [overnight + 20 generations], 5-fluoro-cytosine [15.6 uM] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) aclarubicin [15.63 uM], time [overnight + 20 generations] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) time [overnight + 20 generations], amphotericin B [0.62 uM] het 5,701 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) time [overnight + 20 generations], 5-fluoro-cytosine [15.6 uM], amphotericin B [0.31 uM] het 5,701 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [0.62 uM], time [overnight + 20 generations], 5-fluoro-cytosine [15.6 uM] het 5,701 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) time [overnight + 20 generations], amphotericin B [10 uM] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) time [overnight + 20 generations], borrelidin [15.63 uM] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) time [overnight + 20 generations], cycloheximide [0.03 nM] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) cycloheximide [100 uM], time [overnight + 20 generations] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) time [overnight + 20 generations], daunomycin [125 uM] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) daunomycin [250 uM], time [overnight + 15 generations] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) filipin [100 uM], time [overnight + 20 generations] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [0.31 uM], fluconazole [31.25 uM], time [overnight + 20 generations] het 5,701 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [20 uM], fluconazole [65.3 uM], time [overnight + 20 generations] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [40 uM], time [overnight + 20 generations], fluconazole [65.3 uM] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) time [overnight + 20 generations], itraconazole [8.8 uM], amphotericin B [0.31 uM] het 5,701 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) itraconazole [8.8 uM], time [overnight + 20 generations], amphotericin B [0.62 uM] het 5,701 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) rapamycin [9 nM], time [overnight + 20 generations] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) trichostatin A [3.91 uM], time [overnight + 20 generations] het 5,686 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) tacrolimus [29.80 uM] het 931 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) amphotericin B [148.00 nM] het 880 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) rapamycin [362.00 pM] het 855 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) cycloheximide [667.00 uM] het 1,052 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) beta-caryophyllene alcohol [24.72 uM] het 839 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) daunomycin [22.37 uM] het 818 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) rapamycin [1.00 nM] het 818 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) daunomycin [9.88 uM] het 815 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) nigericin [15.30 uM] het 993 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) rapamycin [4.00 nM] het 881 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) rapamycin [2.00 nM] het 880 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) daunomycin [18.50 uM] het 1,052 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) amphotericin B [100.00 uM] het 818 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) tacrolimus [100.00 uM] het 818 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) aclarubicin [5.55 uM] het 815 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) ikarugamyin [104.00 uM] het 993 Quantitative